Drug Action
Romosozumab is a humanised monoclonal antibody that inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption.
PDF page 798
Loading InternPractice…
Drug reference
Romosozumab is a humanised monoclonal antibody that inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption.
PDF page 798
Severe osteoporosis in postmenopausal women at increased risk of fractures (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 210 mg once a month for 12 months, supplement with calcium and vitamin D, to be administered as two consecutive 105 mg injections at different injection sites into the thigh, abdomen or upper arm
PDF page 798
History of myocardial infarction or stroke—discontinue if occurs during treatment. hypocalcaemia
PDF page 798
Risk factors for cardiovascular disease. risk factors for osteonecrosis of the jaw—consider temporary interruption of romosozumab if occurs during treatment
PDF page 798
Romosozumab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1. The manufacturer of Evenity ® has provided a Prescriber Guide. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2-8°C) and protect from light—consult product literature for further information regarding storage outside the refrigerator.
PDF page 798
▶Common or very common Arthralgia. headache. hypersensitivity. increased risk of infection. muscle spasms. neck pain. skin reactions ▶Uncommon Cataract. hypocalcaemia. myocardial infarction. stroke ▶Rare or very rare Angioedema ▶Frequency not known Atypical femur fracture. cardiovascular event. osteonecrosis of jaw
PDF page 798
Manufacturer advises monitor serum calcium concentration in patients with severe renal impairment, or in those receiving dialysis—increased risk of hypocalcaemia.
PDF page 798
Manufacturer advises to correct hypocalcaemia before therapy is initiated. Monitor for signs and symptoms of hypocalcaemia during therapy.
PDF page 798
There can be variation in the licensing of different medicines containing the same drug. Solution for injection EXCIPIENTS: May contain Polysorbates ▶Evenity (UCB Pharma Ltd) A Romosozumab 90 mg per 1 ml Evenity 105mg/1.17ml solution for injection pre-filled pens | 2 pre-filled disposable injection P £427.75 Dopamine responsive conditions DOPAMINERGIC DRUGS › DOPAMINE RECEPTOR AGONISTS Dopamine-receptor agonists Overview Bromocriptine p. 439 is used for the treatment of galactorrhoea, and for the treatment of prolactinomas (when it reduces both plasma prolactin concentration and tumour size). Bromocriptine also inhibits the release of growth hormone and is sometimes used in the treatment of acromegaly, but somatostatin analogues (such as octreotide p. 1002) are more effective. Cabergoline p. 440 has similar side-effects to bromocriptine, however patients intolerant of bromocriptine may be able to tolerate cabergoline (and vice versa). Quinagolide p. 777 has actions and uses similar to those of ergot-derived dopamine agonists, but its side-effects differ slightly. Suppression of lactation Although bromocriptine and cabergoline are licensed to suppress lactation, they are not recommended for routine suppression (or for the relief of symptoms of postpartum pain and engorgement) that can be adequately treated with simple analgesics and breast support. If a dopamine-receptor agonist is required, cabergoline is preferred. Quinagolide is not licensed for the suppression of lactation.
PDF page 798
Atypical femoral fractures Manufacturer advises patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment. Osteonecrosis of the jaw Manufacturer advises patients should be informed to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling. Hypocalcaemia Manufacturer advises patients should be advised to report symptoms of hypocalcaemia. Patients should receive a package leaflet and patient alert card.
PDF page 798
210 mg once a month for 12 months,
First-line fragment. Read the complete Indications and Dose section above.
PDF page 798